A review of Haemophilus influenzae disease in Europe from 2000–2014: challenges, successes and the contribution of hexavalent combination vaccines

References

• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302–317.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) [Internet]. [cited 2016 Jul 13]. Available from: http://www.cdc.gov/abcs/reports-findings/surv-reports.html
   Google Scholar
• ECDC. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe [Internet]. 2012 [cited 2016 Jul 13]. Available from: http://www.ecdc.europa.eu/en/publications/_layouts/forms/Publication_DispForm.aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1261
   Google Scholar
• Ramsay ME, McVernon J, Andrews NJ, et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis. 2003;188:481–485.
   PubMed Web of Science ®Google Scholar
• Southern J, McVernon J, Gelb D, et al. Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infancy. Clin Vaccine Immunol. 2007;14:1328–1333.
   PubMed Web of Science ®Google Scholar
• Oh SY, Griffiths D, John T, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis. 2008;197:1275–1281.
   PubMed Web of Science ®Google Scholar
• Borrow R, Dagan R, Zepp F, et al. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10:1621–1631.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Scientific conclusions and grounds for the suspension of the marketing authorisation of Hexavac presented by the EMEA [Internet]. 2005 [cited 2016 Nov 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/000298/WC500074684.pdf
   Google Scholar
• Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines. 2008;7:97–115.
   PubMed Web of Science ®Google Scholar
• Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 1992;120:184–189.
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Claesson BA, Lagergård T, et al. Serum antibodies against Haemophilus influenzae type b and tetanus at 2.5 years of age: a follow-up of 2 different regimens of infant vaccination. Scand J Infect Dis. 1996;28:519–523.
   PubMed Web of Science ®Google Scholar
• Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA. 1992;267:1489–1494.
   PubMed Web of Science ®Google Scholar
• Lucas AH, Granoff DM. Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol. 1995;154:4195–4202.
   PubMed Web of Science ®Google Scholar
• Singleton R, Hammitt L, Hennessy T, et al. The Alaska Haemophilus influenzae type b experience: lessons in controlling a vaccine-preventable disease. Pediatrics. 2006;118:e421–429.
   PubMed Web of Science ®Google Scholar
• Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Expert Rev Vaccines. 2016;15:1575–1582.
   PubMed Web of Science ®Google Scholar
• Sawyer LA, McInnis J, Patel A, et al. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine. 1994;12:851–856.
   PubMed Web of Science ®Google Scholar
• Mahmood K, Pelkowski S, Atherly D, et al. Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries. Hum Vaccin Immunother. 2013;9:1894–1902.
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, et al. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063–2068.
   PubMed Web of Science ®Google Scholar
• Kalies H, Verstraeten T, Grote V, et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J. 2004;23:944–950.
   PubMed Web of Science ®Google Scholar
• Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet. 1992;340:592–594.
   PubMed Web of Science ®Google Scholar
• Ladhani SN. Two decades of experience with the Haemophilus influenzae serotype b conjugate vaccine in the United Kingdom. Clin Ther. 2012;34:385–399.
   PubMed Web of Science ®Google Scholar
• McVernon J, Andrews N, Slack MPE, et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361:1521–1523.
   PubMed Web of Science ®Google Scholar
• Spanjaard L, van den Hof S, de Melker HE, et al. [Increase in the number of invasive Haemophilus influenzae type b infections]. Ned Tijdschr Geneeskd. 2005;149:2738–2742.
   PubMedGoogle Scholar
• Schouls LM, van der Ende A, van de Pol I, et al. Increase in genetic diversity of Haemophilus influenzae serotype b (Hib) strains after introduction of Hib vaccination in The Netherlands. J Clin Microbiol. 2005;43:2741–2749.
   PubMed Web of Science ®Google Scholar
• Aracil B, Slack M, Pérez-Vázquez M, et al. Molecular epidemiology of Haemophilus influenzae type b causing vaccine failures in the United Kingdom. J Clin Microbiol. 2006;44:1645–1649.
   PubMed Web of Science ®Google Scholar
• Perrett KP, John TM, Jin C, et al. Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type B conjugate vaccination in early childhood and response to booster. Clin Infect Dis. 2014;58:949–959.
   PubMed Web of Science ®Google Scholar
• Bogaerts H. The future of childhood immunizations: examining the European experience. Am J Manag Care. 2003;9:S30–36.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Hexaxim H-W-2495 [Internet]. 2012 Jun [cited 2016 Jul 13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_for_use_outside_EU/2012/06/WC500129095.pdf
   Google Scholar
• European Medicines Agency - Find medicine - Vaxelis [Internet]. cited 2016 Jul 13. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003982/human_med_001962.jsp&mid=WC0b01ac058001d124
   Google Scholar
• European Centre for Disease Prevention and Control. European Invasive Bacterial Infections Surveillance Network (EU-IBIS) [Internet]. [cited 2016 Jul 14]. Available from: http://ecdc.europa.eu/en/healthtopics/vaccine-preventable-diseases/EU_IBD/Pages/index.aspx
   Google Scholar
• European Centre for Disease Prevention and Control. External quality assessment scheme for Haemophilus influenzae. Technical Report [Internet]. 2014 [cited 2016 Jul 14]. Available from: http://ecdc.europa.eu/en/publications/Publications/haemophilus-influenzae-external-quality-assessment-scheme-2014.pdf
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance Atlas of infectious diseases [Internet]. [cited 2016 Jul 14]. Available from: http://ecdc.europa.eu/en/aboutus/what-we-do/surveillance/Pages/data-access.aspx
   Google Scholar
• World Health Organisation. WHO vaccine-preventable diseases: monitoring system 2016 global summary [Internet]. [cited 2016 Jul 14]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/
   Google Scholar
• World Health Organization. Global and regional immunization profile. European Region. Provisional data as of May 2016 [Internet]. [cited 2016 Jul 14]. Available from: http://www.who.int/immunization/monitoring_surveillance/data/gs_eurprofile.pdf?ua=1
   Google Scholar
• World Health Organization. Global and regional immunization profile. Global. Provisional data as of May 2016 [Internet]. [cited 2016 Jul 14]. Available from: http://www.who.int/immunization/monitoring_surveillance/data/gs_gloprofile.pdf
   Google Scholar
• ECDC European Centre for Disease Prevention and Control. Vaccine Schedule [Internet]. 2015 [cited 2016 Jul 25]. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
   Google Scholar
• ECDC. European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe [Internet]. 2007 [cited 2016 Jul 14]. Available from: http://ecdc.europa.eu/en/publications/Publications/101011_SUR_Surveillance_of_invasive_bacterial_diseases_in_Europe_2007.pdf
   Google Scholar
• Ministerium frauen Gesundheit. Impfplan 2010 Österreich [Internet]. 2009 [cited 2016 Nov 21]. Available from: http://www.jku.at/AS/content/e13901/e13900/e13818/e13817/impfplan_2009_final_ger.pdf
   Google Scholar
• Giufrè M, Cardines R, Caporali MG, et al. Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance. Vaccine. 2011;29:3857–3862.
   PubMed Web of Science ®Google Scholar
• Ciofi degli Atti ML, Cerquetti M, Tozzi AE, et al. Haemophilus influenzae invasive disease in Italy, 1997-1998. Eur J Clin Microbiol Infect Dis. 2001;20:436–437.
   PubMed Web of Science ®Google Scholar
• Terracciano E, Zaratti L, Franco E. [Haemophilus influenzae type b in Italy–after thirty years of vaccination may we lower our guard?]. Ig Sanita Pubbl. 2015;71:539–547.
   PubMedGoogle Scholar
• l’Istituto Superiore di Sanità. Dati di sorveglianza delle malattie batteriche invasive 2007-2010 [Surveillance data of invasive bacterial diseases 2007–2010] (versione 30/06/2013) [Internet]. [cited 2016 Oct 21]. Italian. Available from: http://www.iss.it/binary/mabi/cont/Report_MBI2_2007_2010.pdf
   Google Scholar
• l’Istituto Superiore di Sanità. Dati di sorveglianza delle malattie batteriche invasive aggiornati al 4 aprile 2016 [Surveillance data of invasive bacterial diseases updated April 4, 2016]. [Internet]. [cited 2016 Oct 21]. Italian. Available from: http://www.iss.it/binary/mabi/cont/Report_MBI_20160404.pdf
   Google Scholar
• Hallander HO, Lepp T, Ljungman M, et al. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease. APMIS. 2010;118:878–887.
   PubMed Web of Science ®Google Scholar
• Kalies H, Siedler A, Gröndahl B, et al. Invasive Haemophilus influenzae infections in Germany: impact of non-type b serotypes in the post-vaccine era. BMC Infect Dis. 2009;9:45.
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, von Kries R, Hassenpflug B, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines. Pediatr Infect Dis J. 2001;20:767–774.
   PubMed Web of Science ®Google Scholar
• Kalies H, Grote V, Siedler A, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type b disease: Germany’s experience after 5 years of licensure. Vaccine. 2008;26:2545–2552.
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Canny M, O’Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill. 2005;10:E050929.2.
   Google Scholar
• Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40–C44.
   PubMed Web of Science ®Google Scholar
• Van Eldere J, Slack MPE, Ladhani S, et al. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 2014;14:1281–1292.
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Park L, Borchardt SM. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons > or = 65 years old. Clin Infect Dis. 2007;44:810–816.
   PubMed Web of Science ®Google Scholar
• Adam HJ, Richardson SE, Jamieson FB, et al. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28:4073–4078.
   PubMed Web of Science ®Google Scholar